Fisher & Paykel Healthcare provides FY22 revenue guidance
News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)
Fisher & Paykel Healthcare provides FY22 revenue guidance
Auckland, New Zealand, 23 March 2022 - Fisher & Paykel Healthcare Corporation Limited
today provided revenue guidance for the financial year ending 31 March 2022.
At current exchange rates, the company expects full year operating revenue for the 2022
financial year to be in the range of $1.675 billion to $1.70 billion.
Managing Director and Chief Executive Officer Lewis Gradon said, “Our second half hospital
consumables revenue is currently tracking to be similar to the hospital consumables revenue
that we reported in the first half of the 2022 financial year. This is consistent with reports of the
increasing prevalence of the Omicron variant over the last two months and its associated lower
respiratory intervention requirements, as well as a relatively mild flu season in the Northern
Hemisphere.
“In our Homecare product group, growth in sales of our OSA masks is currently tracking above
our first half growth rate despite supply constraints of treatment hardware in the market.
“Freight rates remain elevated and for the 2022 financial year are expected to impact our long-
term gross margin target of 65% by approximately 250 basis points.
“Regardless of how COVID-19 effects unfold over the short term, we are confident our business
is well-placed to contribute to a positive change in clinical practice and improving outcomes for
respiratory patients in general over the long term”, concluded Mr Gradon.
The company intends to release on Wednesday, 25 May 2022 its financial results for the year
ending 31 March 2022.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive
sleep apnea. The company’s products are sold in over 120 countries worldwide. For more
information about the company, visit our website www.fphcare.com
.
Media & Investor Contacts:
Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 21 713 911
Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 27 807 8073
Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- FBU — Fletcher Building: Fletcher Building FY22 Half Year Results and Dividend2022-02-15
“Fletcher Building Limited, Private Bag 92114, Auckland 1142, 810 Great South Road, Penrose, Auckland 1061, New Zealand Based on our experience in Australia with the COVID-19 Omicron variant, we foresee a potential risk impact on our EBIT in the $25 million to $50 million range.…”